Jazz Pharmaceuticals (JAZZ) PT Lowered to $235 at Barclays
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rallies after Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts JAZZ Hot Sheet
Price: $230.94 +0.52%
Rating Summary:
33 Buy, 5 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 16 | Down: 25 | New: 12
Rating Summary:
33 Buy, 5 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 16 | Down: 25 | New: 12
Join SI Premium – FREE
Barclays analyst Balaji Prasad lowered the price target on Jazz Pharmaceuticals (NASDAQ: JAZZ) to $235.00 (from $240.00) while maintaining a Overweight rating.
You May Also Be Interested In
- AMD (AMD) PT Raised to $600 at DA Davidson
- Revvity Inc (RVTY) PT Raised to $177 at Stifel
- Duolingo Inc. (DUOL) PT Raised to $180 at DA Davidson
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
